Immunicum's patent application regarding the cancer immune primer INTUVAX will be granted in Japan
Gothenburg, Sweden, 2015-11-20 10:05 CET (GLOBE NEWSWIRE) --
Immunicum AB (publ) reported today that the Japan Patent Office (JPO), has announced that it intends to grant a patent relating to the Company's cancer immune primer, INTUVAX.
- We are pleased with the positive news from the Japan Patent Office, which will further strengthen the protection for our main product, says Jamal El-Mosleh, CEO of Immunicum.
The Japanease patent to be granted, with the titel "Improved composition for inhibiting tumor cell proliferation", relates to allogeneic dendritic cells (DCs), stimulated by a specific cocktail, for use in the treatment of cancer by intratumoral injection of the DCs.
Immunicum's vaccine cells are comprised of white blood cells from healthy blood donors, so-called allogeneic dendritic cells, which via a special activation process are developed into highly cancer immunogenic cells when injected intratumorally. The Company's unique cancer immune priming concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells.
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
The company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se
INTUVAX is a cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated white blood cells, so called dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T lymphocytes.
About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains an additional clinical phase I/II study in liver cancer and an upcoming clinical phase I/II-study in gastrointestinal stromal tumors (GIST).